Company Overview of Creabilis SA
Creabilis SA, a clinical stage biotechnology company, engages in the research and development of new drugs for the treatment of dermatology and inflammatory diseases. Its development stage product portfolio includes CT327, a TrkA kinase inhibitor for the treatment of psoriasis and atopic dermatitis; CT340, a TrkA kinase and MAP2K3 kinase inhibitor for the treatment of inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for the treatment of inflammatory conditions, such as lupus, acute liver failure, and fibrosis. The company is also involved in various early stage projects for the development of candidates for dermatological and other indications. Creabilis SA was founded in 2003...
5, Rue JeanMonnet
Founded in 2003
Key Executives for Creabilis SA
Chief Development Officer
Compensation as of Fiscal Year 2014.
Creabilis SA Key Developments
Creabilis Mulls IPO
Aug 16 14
Creabilis SA intends to go for initial public offering (IPO) later in 2014. Eliot Forster told the Sunday Telegraph he is eyeing a public listing for Creabilis. “We are exploring all options at the moment, but our ambition is to look hard at listing, if we can,” said Forster, adding that he would prefer to float the company in London rather than New York. He said the target fundraising will depend on the scale of trial required to satisfy US regulators.
Creabilis SA Appoints Gil Yosipovitch and Praveen Anand to its Scientific Advisory Board
Jul 29 13
Creabilis SA announced that it has appointed Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board. Gil Yosipovitch is the newly announced Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, and is one of the renowned experts in pruritus. Praveen Anand is Professor of Clinical Neurology and Head of the Centre for Clinical Translation at Hammersmith Hospital, Imperial College London, UK.
Creabilis Announces Encouraging Results from Phase IIb Psoriasis Trial
May 23 13
Creabilis has announced results from the company's Phase IIb trial with CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design' drugs. Patients receiving CT327 showed a statistically significant and clinically meaningful reduction in pruritus compared to blinded placebo vehicle. Pruritus was measured using a visual analogue scale (VAS), the accepted regulatory endpoint. The reduction from baseline in pruritus VAS reached 60% for CT327 compared to 20% for vehicle alone (p<0.05). A clinically meaningful reduction in pruritus (VAS greater than or equal to 20mm) was seen in up to 79% of patients for CT327 compared to 36% for vehicle alone (p<0.05). At baseline, 69% of patients reported at least moderate pruritus (VAS > 40mm). An improvement was also seen in the CT327 treated groups versus vehicle in mPASI (modified Psoriasis Area and Severity Index) in all patients. In patients with at least moderate pruritus at the start of the trial, significant reductions in mPASI were observed for CT327 compared to vehicle. There was no significant impact of any dose of CT327 on the IGA (Investigator Global Assessment) endpoint. CT327 was safe and well tolerated with no site application reactions and no systemic exposure. Notably, patients on CT327 reported fewer adverse events and withdrawals due to pruritus than the vehicle treated patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries